Are you a Knight ADRC affiliated researcher with a news article you would like us to post?
Contact Us

Better Cognitive Predictor in People at High Risk of Alzheimer’s Disease (Links to an external site)

The Alzheimer’s disease (AD) drug lecanemab’s recent success in Biogen’s Phase III clinical trials might have more to do with its effect in increasing levels of soluble amyloid-beta than in decreasing amyloid plaques in the brain, the findings of a new study published in the Journal of Alzheimer’s Disease on October 4, 2022, suggests.